logo-loader
CelLBxHealth PLC

Angle PLC - Issue of LTIP Options and Share Options

RNS Number : 5995B
Angle PLC
21 March 2025
 

For immediate release

21 March 2025

 

ANGLE plc ("the Company")

 

Issue of LTIP Options and Share Options

 

 

ANGLE plc (AIM: AGL; OTCQX: ANPCY), a world-leading liquid biopsy company, announces that, under the Remuneration Policy approved by the shareholders at the Annual General Meeting on 11 July 2024 ("the Remuneration Policy"), the Remuneration Committee has approved the grant under the Long-Term Incentive Plan (LTIP) of options (the "LTIP Options") over a maximum of 12,000,000 ordinary shares of £0.10 ("Ordinary Shares"), subject to the performance conditions set out below, to the Company's executive directors. The Remuneration Committee has also approved the issue of up to 13,800,000 share options under its existing share option plans to staff (the "Staff Share Options"). 

 

Share options are issued to align the interest of employees with shareholders and help motivate, reward and retain staff. The allocation of LTIP Options and Staff Share Options approved by the Remuneration Committee also takes into account that, for the third consecutive year, no bonuses for executives and staff were awarded in order to help conserve cash and extend the Company's cash runway.  While a staff share option award was made in 2024, the allocation for executive directors reflects a catch-up award for 2024 as well as a 2025 award following the agreement to waive cash bonus entitlements for both 2023 and 2024 operating years. 

 

Following the issue of these options, the Company will have outstanding options over a total of up to 51,369,480 Ordinary Shares, representing approximately 13.7% of its issued and to be issued share capital, which is within the Remuneration Policy approved limit of up to 16%.

 

The exercise price for the Staff Share Options is 10.00 pence per Ordinary Share, being 2.6% above the Company's closing mid-market share price of 9.75 pence per Ordinary Share on 20 March 2025, being the latest practicable date prior to this announcement. The Staff Share Options are subject to certain service and/or performance conditions over a three-year period.

 

The LTIP Options have performance conditions as set out below, a performance period of three years and an additional holding period of two years. Subject to the rules of the LTIP, awards will vest only to the extent that the performance conditions have been met during the performance period and the underlying shares may only be traded once the holding period is completed. The LTIP Options contain normal "good leaver", "bad leaver" and change of control provisions, and malus and clawback provisions will apply under certain circumstances.

 

The intention of the LTIP is to reward tangible increases in shareholder value, in this case above the share price of the last funding round (15.00 pence per Ordinary Share in June 2024). The performance conditions for the LTIP Options relate to the compound annual growth rate (CAGR) of the share price from this base level over the three-year performance period. As different levels of performance are achieved the number of shares that vest increases up to a maximum as set out below:

                                                                                              




Allocation of LTIP options

Share price CAGR on funding round

Multiple of funding round share price

Multiple of current share price

Proportion vesting

Andrew Newland

Ian Griffiths

Total

< 20%

< 1.73

<2.66

0%

0

0

0

> 20%

> 1.73

>2.66

20%

1,440,000

960,000

2,400,000

> 25%

> 1.95

>3.00

50%

3,600,000

2,400,000

6,000,000

> 30%

> 2.20

>3.38

100%

7,200,000

4,800,000

12,000,000

 

The non-executive directors of the Company do not hold share options.

 

As at 20 March 2025, the Company has 322,641,668 Ordinary Shares in issue.

 

 

The below notification made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Andrew Newland

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

ANGLE plc

b)

 

LEI

 

 

213800BY11K6W3NMS374

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Options over Ordinary shares of £0.10 each

 

 

ISIN:    GB0034330679

 

 

 

b)

 

Nature of the transaction

 

 

Grant of nil-cost LTIP options over ordinary shares under the ANGLE plc LTIP Scheme

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

Nil

 

Up to 7,200,000 dependent on share price performance

 

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

N/A

 

 

 

 

 

 

e)

 

Date of the transaction

 

 

20 March 2025

f)

 

Place of the transaction

 

 

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Ian Griffiths

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Finance Director

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

ANGLE plc 

b)

 

LEI

 

 

213800BY11K6W3NMS374

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Options over Ordinary shares of £0.10 each

 

 

ISIN:    GB0034330679

 

 

 

b)

 

Nature of the transaction

 

 

Grant of nil-cost LTIP options over ordinary shares under the ANGLE plc LTIP Scheme

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

Nil

 

Up to 4,800,000 dependent on share price performance

 

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

N/A

 

 

 

 

 

 

e)

 

Date of the transaction

 

 

20 March 2025

f)

 

Place of the transaction

 

 

Outside a trading venue

 

 

For further information:

 

ANGLE plc

+44 (0) 1483 343434

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

 

 

Berenberg (NOMAD and Broker)

Toby Flaux, Ciaran Walsh, Milo Bonser

 

+44 (0) 20 3207 7800

 

FTI Consulting

Simon Conway, Ciara Martin

Matthew Ventimiglia (US)

 

 

+44 (0) 203 727 1000

+1 (212) 850 5624

 

 

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.

 

Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com

 

Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product:

 

The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer.  The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood.  The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays.  The end user is responsible for the validation of any downstream assay.  The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEADDEALASEAA
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

London BTC Company, CelLBxHealth, Anglo Asian Mining, Galliford Try,...

London BTC Company Ltd (LSE:BTC, OTCQB:VINZF) has staked 36 mineral claims at its new Black Star gold-silver project in Nevada, with surface samples returning up to 16.23 grams per tonne gold. It's the company's fourth Nevada project and sits just 16 miles from the 16.4 million ounce Hycroft...

on 07/15/2026

7 min read